DRAD Digirad Corporation

Digirad Corporation (www.digirad.com) (NASDAQ:DRAD) has been named, for the 4th year in a row, to Deloitte's prestigious Technology Fast 50 Program for San Diego, a ranking of the 50 fastest growing technology, media, telecommunications and life sciences companies in the area by Deloitte & Touche USA LLP, one of the nation's leading professional services organizations. Rankings are based on percentage revenue growth over five years from 2001-2005. According to Mark L. Casner, president and chief executive officer of Digirad, the company has executed many initiatives designed to grow market share and improve operational efficiencies in order to reduce costs and enhance margins, all of which have contributed to Digirad's 141 percent growth rate from 2001-2005. "We continue to increase our market position in nuclear cardiology by offering exclusive imaging products and services to cardiologists and internists through Digirad Imaging Solutions' (DIS) nuclear cardiology FlexImaging(R) services," said Casner. DIS provides nuclear imaging equipment (mobile or fixed), accredited staff and licensing under annual contracts to physicians' offices one or more days each week. "We continue to expand our market coverage by providing quality programs that exceed our customers' expectations," said Casner. Casner added that Digirad has seen increased acceptance of its solid-state Cardius(R) dedicated nuclear cardiology imaging systems. The new Cardius XPO camera series debuted at the Society of Nuclear Medicine (SNM) in June and was featured at the American Society of Nuclear Cardiology (ASNC) last week in Montreal. The XPO series features new Solidium(R) high-definition solid-state (HDSD) digital detector technology, a new design allowing imaging of patients weighing up to 500 pounds, and single, dual and triple-head configurations offering up to 38 percent faster image acquisition times than conventional dual head systems. "Deloitte's San Diego Technology Fast 50 companies have shown the strength, vision and tenacity to succeed in today's very competitive technology environment," said Theresa Drew, Managing Partner, Deloitte & Touche LLP in San Diego. "We applaud the successes of Digirad and acknowledge it as one of the very few to accomplish such a fast growth rate over the past five years." To qualify for the Technology Fast 50, companies must have had operating revenues of at least $50,000 in 2001 and $5,000,000 in 2005, be headquartered in North America, and be a company that owns proprietary technology or proprietary intellectual property that contributes to a significant portion of the company's operating revenues; or devotes a significant proportion of revenues to the research and development of technology. Using other companies' technology or intellectual property in a unique way does not qualify. Winners of the 16 regional Technology Fast 50 programs in the United States and Canada are automatically entered in Deloitte's Technology Fast 500 program, which ranks North America's top 500 fastest growing technology, media, telecommunications and life sciences companies. For more information on Deloitte's Technology Fast 50 or Technology Fast 500 programs, visit www.fast500.com. About Digirad Digirad Corporation develops, manufactures and markets solid-state, digital gamma cameras to hospitals, imaging centers and physician offices. Digirad offers a comprehensive line of solid-state nuclear gamma cameras that produce high-quality images for use in the detection of many medical conditions, including cardiovascular disease. Digirad's cameras are unique as their lightweight and compact design allows them to fit easily into small office spaces. Digirad's wholly owned subsidiaries Digirad Imaging Solutions and Digirad Imaging Systems offer a comprehensive, mobile imaging leasing and services program for physicians who wish to perform in-office nuclear cardiology procedures but do not have the patient volume, capital or resources to justify purchasing a gamma camera. For more information, please visit www.digirad.com. Digirad(R), Digirad Imaging Solutions(R), FlexImaging(R) and Cardius(R) are registered trademarks of Digirad Corporation. About Deloitte Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms and their respective subsidiaries and affiliates. As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other's acts or omissions. Each of the member firms is a separate and independent legal entity operating under the names "Deloitte", "Deloitte & Touche", "Deloitte Touche Tohmatsu" or other related names. Services are provided by the member firms or their subsidiaries or affiliates and not by the Deloitte Touche Tohmatsu Verein. Deloitte & Touche USA LLP is the US member firm of Deloitte Touche Tohmatsu. In the US, services are provided by the subsidiaries of Deloitte & Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting LLP, Deloitte Financial Advisory Services LLP, Deloitte Tax LLP and their subsidiaries), and not by Deloitte & Touche USA LLP. Forward-Looking Statements Digirad cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts and use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" and other words and terms of similar meaning in connection with a discussion of future operating or financial performance or events. Examples of such statements include the statements regarding the Cardius(R) 3 XPO's advancements in patient comfort, imaging speed and image quality, Digirad's ability to meet or exceed customer expectations, Digirad's ability to improve operational efficiencies in order to reduce costs and enhance margins, and Digirad's ability to grow and expand its services and products businesses. The inclusion of these and other forward-looking statements should not be regarded as a representation by Digirad that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Digirad's business including, without limitation: the degree to which Digirad's camera systems and related services will be accepted by physicians and hospitals some of whom may experience reliability issues or technical problems; the ability of Digirad to effectively market, sell and distribute its medical devices, and related services given its limited capabilities in these areas; Digirad's ability to manage risks relating to product liability, warranty claims, recalls, property damage and personal injury with respect to its imaging systems; and other risks detailed in Digirad's Securities and Exchange Commission filings, including its Annual Report on Form 10-K and other reports filed with the Securities and Exchange Commission. Given these uncertainties, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Digirad undertakes no obligation to revise or update this press release including the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.